• Incanthera

    Revolutionary Cancer Therapies

    Innovative technology providing groundbreaking drug solutions

  • Incanthera

    Excellence in Oncology Research

    Originating from world-recognised, research-led Universities

  • Incanthera

    Delivering Improved Patient Outcomes

    Targeted technologies yielding greater efficacy with fewer side effects

Our Story

  • A pipeline-rich technology company with revolutionary products
  • Innovative targeting pro-drug technologies
  • Developing and bringing to commercial partners novel treatments for solid tumours (cancers)
  • Incanthera originated as a ‘spin-out’ from the University of Bradford’s Institute of Cancer Therapeutics
  • Funded through research grants from CRUK, YCR, the Universities of Bradford, Salford and Leicester with equity investment from the North West Fund for Biomedical, managed by SPARK Impact Ltd, Advent International and from private individuals
  • Massive drug discovery market potential
Our Story

Cancer Today

  • 1 in 2 patients survive cancer for ten or more years (CRUK)
  • 24% to 50% cancer survival in the UK has doubled in the last forty years
  • Incanthera

    In Development: ICT01-2588

    ICT01-2588 is a targeted vascular disrupting agent, developed by the Institute of Cancer Therapeutics with funding from Cancer Research UK, Yorkshire Cancer Research and University of Bradford.

    View all technologies
  • Incanthera

    In Development: ICT03-Es5

    ICT03-Es5 is a targeted, bio-reductive cytotoxic agent, developed by the University of Salford and the Patterson Institute, University of Manchester.

    View all technologies
  • Incanthera

    In Development: ICT04-CYP

    ICT04-CYP is a targeted, cyp-activated chemotoxin, developed by the De Montford University (Leicester).

    View all technologies
Incanthera

Meet The Team

Highly experienced team drawn from commercial, scientific and regulatory backgrounds

Find out more about our team